Search results for "medicine.drug_class"

showing 10 items of 2726 documents

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct

CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor

2002

CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…

medicine.medical_specialtymedicine.drug_classPhenylcarbamatesPharmacologyHippocampusArticleCyclic N-Oxideschemistry.chemical_compoundNeurochemicalAlzheimer DiseaseDopamineInternal medicinemedicineAnimalsBiogenic MonoaminesAmino AcidsNeurotransmitterButyrylcholinesteraseCholinesterasePharmacologybiologybusiness.industryGlutamate receptoracetylcholinesterase inhibitors; alzheimer's disease; amino acids; chf2819; ganstigmine; neurotransmitters; rat hippocampusAcetylcholineRatsNeuropsychology and Physiological PsychologyEndocrinologyAcetylcholinesterase inhibitorchemistrybiology.proteinCarbamatesCholinesterase InhibitorsbusinessAcetylcholinemedicine.drug
researchProduct

Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics

2013

Background The cardiac hormone atrial natriuretic peptide (ANP) induces natriuresis, vasodilation and inhibits aldosterone through the activation of the guanylyl cyclase A receptor (GC-A) and the second messenger cGMP. ANP possesses also metabolic properties enhancing lipolysis and release of the adipokine adiponectin. Previous studies in general populations reported that the minor G allele of the ANP genetic variant rs5068 is associated with increased circulating levels of ANP and B-type natriuretic peptide, lower blood pressure (BP), and reduced risk of hypertension. We recently reported that in the general population from Olmsted County, MN, USA the G allele of rs5068 is associated not o…

medicine.medical_specialtymedicine.drug_classPopulationAdipokineBioinformaticsNatriuresischemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineNatriuretic peptidePharmacology (medical)educationPharmacologyeducation.field_of_studyAldosteroneAdiponectinbusiness.industrymedicine.diseaseEndocrinologychemistrycardiovascular systemOral PresentationMetabolic syndromebusinesshormones hormone substitutes and hormone antagonistsBMC Pharmacology and Toxicology
researchProduct

Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.

2007

The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patients with inoperable bowel obstruction. A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed. Five reports fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globa…

medicine.medical_specialtymedicine.drug_classPopulationOctreotideMuscarinic AntagonistsPlaceboSettore MED/42 - Igiene Generale E ApplicataOctreotidelaw.inventionRandomized controlled trialGastrointestinal AgentslawAdrenal Cortex HormonesInternal medicineNeoplasmsButylscopolammonium BromidemedicineHumansStage (cooking)educationinoperable malignant bowel obstruction treatmentGeneral Nursingeducation.field_of_studybusiness.industryqualitative systematic reviewCancermedicine.diseaseSurgeryBowel obstructionAnesthesiology and Pain Medicineinoperable malignant bowel obstruction treatment; qualitative systematic review; management of bowel obstructionCorticosteroidNeurology (clinical)businessIntestinal Obstructionmedicine.drugmanagement of bowel obstructionJournal of pain and symptom management
researchProduct

The Inhibitory Effects of Prednisone, 16-Methylen-Prednisolone, and Acth on Con-A Induced Lymphokines (Interferon-Y) as Measured by the Chemiluminesc…

1988

When lymphocytes are stimulated with mitogens or antigens they are enhanced via a cascade of lymphokines to produce interferon-y (IFN-y). IFN-y augments the H2O2 secretion of human monocytes which indirectly can be measured by chemiluminescence. We tested prednisone, 16-methylen-prednisolone and ACTH for their effect to inhibit the Con-A induced stimulation of the chemiluminescence-activity. All three hormones inhibited significantly the stimulation: prednisone up to 52.5% (concentration = 150 micrograms/ml, p = 0.000005), 16-methylen-prednisolone up to 22.5% (concentration = 2.5 micrograms/ml, p = 0.006) and ACTH up to 33% (concentration = 10 micrograms/ml, p = 0.0036).

medicine.medical_specialtymedicine.drug_classPrednisoloneImmunologyDose-Response Relationship ImmunologicStimulationAdrenocorticotropic hormoneToxicologyMonocytesInterferon-gammaAdrenocorticotropic HormoneInternal medicineConcanavalin AmedicineHumansImmunology and AllergyInterferon gammaPharmacologybiologybusiness.industryMonocyteLymphokineHydrogen PeroxideGeneral Medicinemedicine.anatomical_structureEndocrinologyConcanavalin ALuminescent Measurementsbiology.proteinPrednisolonePrednisoneCorticosteroidbusinessmedicine.drugImmunopharmacology and Immunotoxicology
researchProduct

Asthma-COPD overlap syndrome: recent advances in diagnostic criteria and prognostic significance.

2017

The term asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been proposed for individuals with features of both asthma and COPD. Several attempts have been done to define ACOS on the basis of medical history, symptoms, and functional findings. The main diagnostic criteria include airflow obstruction with a strong although incomplete reversibility to bronchodilation tests, a significant exposure to cigarette or biomass smoke, and a history of atopy or asthma. Additional diagnostic elements include eosinophilic airway and systemic inflammation, a good response to corticosteroid treatment, and a high concentration of exhaled nitric oxide. ACOS should be distinguish…

medicine.medical_specialtymedicine.drug_classPrognosiComorbidity030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineBronchodilatorMedicineHumansMedical historyFunctional abilityAsthmaCOPDbusiness.industryRisk FactorMedicine (all)SmokingOverlap syndromeGeneral Medicinemedicine.diseasePrognosisComorbidityAsthmarespiratory tract diseases030228 respiratory systemExhaled nitric oxidebusinessHumanMinerva medica
researchProduct

Maintenance therapy in gastro-oesophageal reflux disease.

2005

Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics. In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylori-negative or H. pylori-positive patients have not materialized, while no cases of intesti…

medicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyDrug Administration ScheduleEsomeprazoleHiatal herniaPharmacotherapyMaintenance therapyInternal medicinemedicineHumansPharmacology (medical)SurvivorsSurgical teambusiness.industryEsophageal diseaseDecision TreesHeartburnEndoscopyProton Pump Inhibitorsmedicine.diseaseAnti-Ulcer Agentsdigestive system diseasesGastroesophageal Refluxmedicine.symptombusinessmedicine.drugDrugs
researchProduct

<p>Future perspectives of anticholinergics for the treatment of asthma in adults and children</p>

2019

Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinic…

medicine.medical_specialtymedicine.drug_classPsychological intervention030204 cardiovascular system & hematologyAsthma managementPlacebo03 medical and health sciences0302 clinical medicineAnticholinergicMedicinePharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsDisease management (health)Intensive care medicineAsthmaChemical Health and Safetybiologybusiness.industryGeneral MedicineLamabiology.organism_classificationmedicine.diseaserespiratory tract diseasesClinical trialbusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct

Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice.

2010

The constitutive androstane receptor (CAR) is a nuclear receptor expressed in the liver and involved in xenobiotic metabolism. The aim of this study was to assess whether pharmacological CAR activation could affect neutral sterol and bile acid elimination under conditions of cholesterol overload.Wild type, Car-/-, ApoE-/-, and low-density lipoprotein receptor (Ldlr)-/- mice fed a western-type diet were treated with the CAR agonist TCPOBOP.CAR activation was associated with a decrease in faecal cholesterol output related to the repression of the Abcg5/g8 cholesterol transporters. In contrast, TCPOBOP treatment induced a marked increase (up to three fold, p0.01) in the elimination of faecal b…

medicine.medical_specialtymedicine.drug_classPyridinesLipoproteinsBiological Transport ActiveGene ExpressionReceptors Cytoplasmic and NuclearHyperlipidemiasBiologyCholesterol 7 alpha-hydroxylaseBile Acids and Saltschemistry.chemical_compoundFecesMiceApolipoproteins EInternal medicineConstitutive androstane receptormedicineAnimalsHomeostasisATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorConstitutive Androstane ReceptorMice KnockoutHepatologyBile acidCholesterolReverse cholesterol transportATP Binding Cassette Transporter Subfamily G Member 8Cholesterol HDLAtherosclerosisSterolMice Inbred C57BLEndocrinologyCholesterolchemistryLiverReceptors LDLLDL receptorlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersJournal of hepatology
researchProduct

Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

2021

Thrombosis and haemostasis 122(4), 552-559 (2022). doi:10.1055/a-1549-6556

medicine.medical_specialtymedicine.drug_classPyridonesAdministration OralHemorrhagePharmacokineticsRivaroxabanInternal medicineAtrial FibrillationmedicineHumansProspective StudiesRegistriesRivaroxabanbusiness.industryAnticoagulantAnticoagulantsHematologyEmergency situationsConfidence intervalDabigatranClinical trialApixabanObservational studybusinessmedicine.drug
researchProduct